Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza a (h1n1) 2009 monovalent vaccine (Novartis)
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intranasal
01
Overview
An influenza vaccine specifically formulated against the 2009 pandemic H1N1 strain A/California/7/2009 (H1N1)v. It has been available in two primary formulations: an inactivated split-virion intramuscular vaccine and a live-attenuated, cold-adapted, temperature‑sensitive intranasal vaccine. The inactivated vaccine contains 15 mcg hemagglutinin per 0.5 mL dose and induces protective antibodies against H1N1 by presenting viral antigens without replication. The live-attenuated intranasal vaccine replicates locally in the nasopharynx to elicit mucosal and systemic immunity. Primary indication is active immunization to prevent influenza disease caused by pandemic H1N1 2009 virus in approved age groups. Multiple manufacturers produced monovalent H1N1 vaccines under public health emergency programs beginning in 2009.
- Other names
- a(h1n1) influenza vaccineinfluenza h1n1 vaccinepandemic h1n1 2009 monovalent vaccineinfluenza a (h1n1) 2009 monovalent vaccine live, intranasalinfluenza a (h1n1) 2009 monovalent vaccine, inactivated
02
Targets
NeuraminidaseHA (Hemagglutinin)
Beyond the preview
Go deeper on influenza a (h1n1) 2009 monovalent vaccine (Novartis).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza a (h1n1) 2009 monovalent vaccine (Novartis).